The Research of Efficacy and Safety of Sacubitril/Valsartan in Elderly Patients With Heart Failure
Objective To investigate the effect and safety of sacubitril/valsartan on elderly patients with heart failure.Methods A total of 282 elderly patients diagnosed with heart failure in Beijing Fengtai Hospital from January 2021 to June 2022 were selected.According to the results of lottery,the patients were divided into the treatment group(n=142)and the control group(n=140).The control group was given conventional anti-heart failure drugs,including digitoxin cardiac drugs,diuretics,β-blockers,aldosterone receptor antagonists,angiotensin Ⅱreceptor antagonists,angiotensin converting enzyme inhibitors(ACEI)and vasodilators,and the drug dosage was adjusted according to the individual patients.The treatment group was given sacubitril/valsartan on the basis of conventional heart failure treatment drugs,the initial dose was 50 mg,twice/day,and then gradually increased to 200 mg,twice/day according to tolerance.The results of 6 minutes walking test(6MWT),left ventricular ejection fraction(LVEF),left ventricular short axis shortening rate(FS),plasma N-terminal brain natriuretic peptide(NT-proBNP),renal function and blood pressure were compared between the two groups before and after treatment.Results After treatment,the 6MWT of the treatment group was(304.12±41.51)m,which was higher than(224.25±35.29)m of the control group(P＜0.05).The LVEF and FS in the treatment group were(44.72±6.74)％and(21.72±4.34)％,respectively,higher than(40.31±8.42)％and(14.63±4.11)％in the control group(P＜0.05).The level of NT-proBNP in the treatment group was(1 396.05±42.35)pg/mL,which was lower than(3 421.42±52.32)pg/mL in the control group(P＜0.05).No adverse reactions such as hypotension and deterioration of renal function were observed during the whole course of treatment.Conclusion Sacubitril/valsartan has shown good safety and efficacy in the treatment of elderly patients with heart failure.
NETL
NSTL
万方数据
